Salsalate, an old, inexpensive drug with potential new indications: A review of the evidence from 3 recent studies

American Health and Drug Benefits

Volumn 7, Issue 4, 2014, Pages 231-235

  Anderson, Kenneth ^a   Wherle, Lance ^a   Park, Min ^a   Nelson, Kenneth ^a   Nguyen, Loida D ^b  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; FATTY ACID; GLUCOSE; GLYCOSYLATED ALBUMIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SALSALATE; TRIACYLGLYCEROL;

ARTICLE; DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HEADACHE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTOLIC BLOOD PRESSURE; TINNITUS;

EID: 84903376665     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. National Diabetes Information Clearinghouse (NDIC). Insulin resistance and prediabetes. http://diabetes.niddk.nih.gov/dm/pubs/insulinresistance/#relate2014. Accessed June 1, 2014.
2. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(suppl 1):S14-S80.
3. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IκK-beta and NF-kappaB. Nat Med. 2005;11:183-190.
4. Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013;56:714-723.
5. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116:151-157.
6. Centers for Disease Control and Prevention. Diabetes public health resource: prediabetes. Updated August 13, 2012. www.cdc.gov/diabetes/consumer/prediabetes.htm. Accessed March 16, 2014.
7. Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290.
8. Knowler WC, Barrett-Connor E, Fowler SE, et al; for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
9. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25:2165-2171.
10. Chiasson JL, Josse RG, Gomis R, et al; for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
11. Yang WY, Lixiang L, Jinwu Q, et al. The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicentre prospective study. Chin J Endocrinol Metab. 2001;17:131-136.
12. Jack DB. One hundred years of aspirin. Lancet. 1997;350:437-439.
13. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255-258.
14. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26:203-234.
15. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680-6684.
16. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77-80.
17. Goldfine AB, Fonseca V, Jablonski KA, et al; for the Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013;159:1-12.
18. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437-446.
19. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Iκkbeta. Science. 2001;293:1673-1677. Erratum in:Science. 2002;295:277.
20. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109:1321-1326.
21. Faghihimani E, Aminorroaya A, Rezvanian H, et al. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes. Endocr Pract. 2012;18:826-833.
22. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31:289-294.